Cirius Therapeutics

OverviewSuggest Edit

Cirius Therapeutics, a clinical-stage pharmaceutical company which is developing a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis. Through its novel insulin sensitizing mechanism of action, the insulin sensitizer has a potential to resolve the underlying pathophysiology of NASH. 

TypePrivate
Founded2016
HQKalamazoo, MI, US
Websiteciriustx.com

Latest Updates

Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cirius Therapeutics

Bob Baltera

Bob Baltera

CEO
Howard C. Dittrich

Howard C. Dittrich

Chief Medical Officer
Brian K. Farmer

Brian K. Farmer

Chief Financial Officer and Chief Business Officer
Jerry Colca

Jerry Colca

Chief Scientific Officer
Julie Iwashita

Julie Iwashita

Vice President of Clinical Operations
Angeline Shashlo

Angeline Shashlo

Vice President, Development
Show more

Cirius Therapeutics Office Locations

Cirius Therapeutics has offices in Kalamazoo and San Diego
Kalamazoo, MI, US (HQ)
Haymarket Building, 161 E Michigan Ave 4th Floor
San Diego, CA, US
12651 High Bluff Dr #150
Show all (2)

Cirius Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Cirius Therapeutics total Funding

$40 m

Cirius Therapeutics latest funding size

$40 m

Time since last funding

5 years ago

Cirius Therapeutics investors

Cirius Therapeutics's latest funding round in April 2017 was reported to be $40 m. In total, Cirius Therapeutics has raised $40 m
Show all financial metrics

Cirius Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Cirius Therapeutics Online and Social Media Presence

Embed Graph

Cirius Therapeutics News and Updates

Cirius Therapeutics Announces Presentation of Interim Data from Phase 2b Clinical Study of MSDC-0602K at The International Liver Congress 2019

SAN DIEGO and KALAMAZOO, Mich., April 12, 2019 /PRNewswire/ -- Cirius Therapeutics announced today that positive results from an interim analysis of exploratory endpoints from the EMMINENCE trial, its ongoing Phase 2b clinical trial evaluating MSDC-0602K in 402 patients diagnosed with...

Cirius Therapeutics Blogs

John R. Snyder, CPA

Vice President, Finance and Corporate Controller The post John R. Snyder, CPA appeared first on Cirius.

Andrew Knudten, M.B.A

Chief Technical Officer The post Andrew Knudten, M.B.A appeared first on Cirius.

Elaine Sun

The post Elaine Sun appeared first on Cirius.

Cirius Therapeutics Frequently Asked Questions

  • When was Cirius Therapeutics founded?

    Cirius Therapeutics was founded in 2016.

  • Who are Cirius Therapeutics key executives?

    Cirius Therapeutics's key executives are Bob Baltera, Howard C. Dittrich and Brian K. Farmer.

  • Who are Cirius Therapeutics competitors?

    Competitors of Cirius Therapeutics include Alembic Pharmaceuticals, PPD and Genentech.

  • Where is Cirius Therapeutics headquarters?

    Cirius Therapeutics headquarters is located at Haymarket Building, 161 E Michigan Ave 4th Floor, Kalamazoo.

  • Where are Cirius Therapeutics offices?

    Cirius Therapeutics has offices in Kalamazoo and San Diego.

  • How many offices does Cirius Therapeutics have?

    Cirius Therapeutics has 2 offices.